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Purpose: To investigate the effects of ursolic acid (UA) on expressions of ERK1, C-Jun, C-Myc and 
Cyclin D1 in Human Umbilical Vein Endothelial Cells (HUVEC), and to explore the mechanism of anti-
cancer activity of UA on glioma.  
Methods: HUVEC was treated with UA (0, 31.5, 62.5, 125, 250, 500 μg/mL) for 24 h, and 125 μg/mL for 
0, 12, 24, 48 h, respectively) and PD98059 in vitro. Real-time polymerase chain reaction (RT-PCR) was 
performed to measure the endogenous mRNA levels of ERK1, C-Jun, C-Myc, and Cyclin D1, and 
Western blotting was used to determine the expressions of ERK1, C-Jun, C-Myc, and Cyclin D1 
proteins.  
Results: The results show that the mRNA levels of ERK1, C-Jun, C-Myc, and Cyclin D1 were down-
regulated, following treatment with UA (in a dose- and time-dependent manner) and PD98059 (p < 
0.05). In addition, the protein expressions of ERK1, C-Jun, C-Myc, and cyclin D1 were all significantly 
down-regulated, after treatment with UA (in a dose- and time-dependent manner) and PD98059 (p < 
0.05). 
Conclusion: The findings indicate that UA can significantly inhibit the generation of vascular endothelial 
cells of glioma by down-regulating the expressions of ERK1, C-Jun, C-Myc and Cyclin D1 of ERK signal 
transduction pathway.  
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Ursolic acid (UA) is a pentacyclic triterpenoid 
isolated from Chinese herbal medicine and exists 
widely in Bearberry, Ligustrum lucidum. 
Pharmacological studies indicate that it has 
many biological effects [1]. Recent investigations 
suggest that UA not only has wide resistance to 
the effects of carcinogens, but also inhibits 
endothelial cell proliferation [2] and tumor 
formation [3]. It has drawn increasing interest as 
one of the most promising cancer 
chemopreventive drugs in the world; however, 
the mechanism of its action is still unclear. 
Recently, it was reported that UA functions as an 
anti-proliferation agent of U87 glioma cells [4].  
 
The malignant proliferation of C6 glioma cells 
can be inhibited by inhibiting the activity of ERK 
signaling pathway [5]. Furthermore, it has also 
been confirmed that VEGF can promote 
endothelial cell mitosis by activation of ERK 
signaling pathway. From results of the previous 
investigations, we believe that UA may inhibit the 
proliferation of astrocyte tumor vascular 
endothelial cells by inhibiting ERK signaling 
pathway, thereby inhibiting the growth of glioma. 
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In the present study, the effects of UA on ERK1, 
C-Jun, C-Myc, Cyclin D1 expressions in HUVEC 
were investigated with malignant glioma vascular 
endothelial cells by using RT-PCR and Western 
blot. The present investigation is designed to 
study the molecular mechanisms by which UA 
inhibits tumor cell proliferation, as well as 
develop a new biological target and new ideas in 
glioma biological treatment.  
 
Table 1: Primers used for PCR 






HUVEC cell lines were provided by the 
Department of Pathology, Chongqing Medical 
University, P.R. China. HUVEC were placed in 
RPMI1640 medium with 20 % fetal calf serum 





RPMI1640 culture medium (Hyclone, USA); 
Standard FBS (Hangzhou Sijiqing Biological 
Engineering Materials Co, Ltd, China); ursolic 
acid (Xu Huang Plant Science Technology 
Development Co., Ltd. in Shanxi, China); 
PD98059 (Promaga, USA); DNA Marker 
[Tiangen Biotech (Beijing) Co, Ltd, China]; Biozol 
RNA extraction kit (Bioflux, Japan); RT-PCR 
reaction kit (TaKaRa); PRO-PREPTM protein 
extracts (SBS Genetech Co, Ltd, Beijing, China); 
Bradford Protein Assay Kit (Shanghai Sangon 
Biological Engineering Technology & Services 
Co, Ltd, China); Page Ruler TMP restained 
Protein Ladder (Fermentas USA); PVDF 
membrane (Millipore, USA); Western Blotting 
Luminol Reagent (Santa Cruz, USA); β-actin 
(C4) antibody (Santa Cruz USA); C-Myc antibody 
(Chemicon USA); C-Jun antibody (Santa Cruz, 
USA); ERK1 antibody (Santa Cruz USA); 
CyclinD1 antibody (Santa Cruz, USA); 
Horseradish peroxidase labeled goat anti-rabbit 
IgG (Beijing zhongshan Goldenbridge 
Biotechnology Co, Ltd, China); Horseradish 
peroxidase labeled goat anti-mouse IgG (Beijing 
zhongshan Goldenbridge Biotechnology Co, Ltd, 
China). 
 
RT-PCR examination and ERK1, C-Myc, C-Jun 
and Cyclin D1 mRNA expression 
 
Cells were harvested, and the total RNA was 
extracted according to BIOZOL reagent 
instruction manual. Total RNA was used for 
cDNA synthesis by reverse transcription, and 
cDNA of ERK1, C-Myc, C-Jun, Cyclin D1 and β-
actin were amplified by PCR. All mRNA primers 
were designed by Primer Premier 5.0 and 
synthesised by SBS Genetech Co, Ltd. The 
primers used for the PCR are in Table 1. PCR 
was performed according to the manufacturer’s 
instructions of RT-PCR reaction kit (TaKaRa, 
Japan). Amplification products were analyzed on 
1.0 % agarose gel electrophoresis and computer 
image analysis meter. Agarose gel electro-
phoresis was undertaken to analyze the PCR 
products and their photos collected. 
Electrophoresis band intensities of ERK1, C-Myc, 
C-Jun, CyclinD1 mRNA/β-actin were determined 
by imaging analysis system and statistical 
analysis software and the optical density (OD) of 
ERK1, C-Myc,C-Jun ,Cyclin D1 mRNA/β-actin 
calculated. 
 
Expressions of ERK1, C-Myc, C-Jun and 
CyclinD1 proteins 
 
Cells were harvested, and the total protein was 
extracted. Then, equal amounts of protein (40 
μg) were separated by sodium dodecyl 
sulfate/polyacrylamide gel electrophoresis 
(SDS/PAGE), blotted on polyvinylidene difluoride 
(PVDF), and probed with rabbit anti- human 
ERK1 or C-Myc or C-Jun or Cyclin D1 polyclonal 
anti-body, and subsequently with goat anti-
rabbit/HRP, and detected by chemilumine-
scence. To measure protein loading, antibodies 
directed against β-actin were used. Comparison 
and analysis of area and gray intensity of 
electrophoresis bands were performed by the 
Quantity one 1D gel analysis software (version 
4.6.2, Bio-Rad).  
Gene 
name Primer sequence 
Length 
(bp) 






C-Myc F: 5’-AGGCGAACACACAACGTCTT-3’ 
 R: 5’-TTGGACGGACAGGATGTATGC-3’ 
156 
C-Jun F: 5’-TGGAAACGACCTTCTATGACGA-3’ 






 R: 5’-ATCCAGGTGGCGACGATCT-3’ 
174 
β-actin F: 5’-AACCGCGAGAAGATGACCCAG-3’ 
 R: 5’-CCACAGGACTCCATGCCCAG-3’ 
467 






Ye et al 




Statistical analysis  
 
All of the data are presented as mean ±SD, and 
were evaluated with one-way ANOVA followed 
by Dunnett multiple comparisons post-test 
between different groups. Statistical analysis was 
carried out using SPSS software (SPSS for 
Windows, version 15.0, SPSS Inc, USA) with the 




mRNA expression of ERK1, C-Myc,C-
Jun,Cyclin D1 
 
The results show that expression of ERK1,C-
Myc,C-Jun,CyclinD1 mRNA of HUVEC in group 
1(treated with 125μg/ml UA) and group 2(treated 
with PD98059 100μmol/L) were significantly 
lower than one of blank control group (p < 0.05), 
as Figure 1 indicates.  
 
 
Figure 1: mRNA expressions of ERK1, c-Jun, c-Myc, 
Cyclin D1 in HUVEC treated with Ursolic acid and 
PD98059. M: Marker; 1-3 represented blank control 
group, Ursolic acid group and PD98059 group, 
respectively. 
 
After HUVEC were treated with different UA 
doses (0, 31.5, 62.5, 125, 250, 500 μg/mL), the 
expression of ERK1, C-Myc, C-Jun, Cyclin D1 
mRNA decreased with UA dosage increase and 
then the expression of ERK1, C-Myc, C-Jun, 
CyclinD1 mRNA were significantly different 
beginning from 125μg/ml UA dosage between 
groups treated with different dosage and control 
group, among groups treated with different 
dosage. The differences were statistically 




Figure 2: mRNA Expressions of ERK1, c-Jun, c-Myc, 
Cyclin D1 in HUVEC treated with different Ursolic acid 
dosage. M: Marker;1-6 represented 1.0, 31. 5, 62.5, 
125 , 250 and 500 μg/mL, respectively. 
 
Further, after HUVEC were treated with 
125μg/ml UA dosage, the PCR results showed 
that the expressions of ERK1, C-Myc, C-Jun, 
Cyclin D1 mRNA decreased with time and then 
the expression of ERK1, C-Myc, C-Jun, CyclinD1 
mRNA were significantly different beginning from 
the 12th hour between different time groups and 
control group ,among different time groups 
(Figure 3). The differences are statistically 
significant (p < 0.05). 
 
Expressions of ERK1, C-Myc, C-Jun, and 
Cyclin D1 
 
Western blot results were obtained from image 
analysis (Figure 4). The results indicate that 
expression of ERK1, C-Myc, C-Jun, CyclinD1 of 
HUVEC in UA and PD98059 groups were 
significantly lower than that of control (p < 0.05).  
 
After HUVEC were treated with different UA 
doses (0, 31.5, 62.5, 125, 250 and 500 μg/mL), 
the expressions of ERK1, C-Myc, C-Jun, Cyclin 
D1 decreased with increase in UA (Figure 5); the 
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expressions of ERK1, C-Myc, C-Jun, CyclinD1 
mRNA were significantly different at UA doses of 
125, 250 and 500 μg/mL (p < 0.05).  
 
 
Figure 3: mRNA Expressions of ERK1, c-Jun, c-Myc, 
Cyclin D1 in HUVEC treated with ursolic acid at 
different times. M: Marker;1-4 represented 1, 12, 24 
and 48 hours, respectively 
 
 
Figure 4: Expressions of ERK1, c-Jun, c-Myc, Cyclin 
D1 in HUVEC treated with Ursolic acid and PD98059 
 
In addition, following treatment of HUVEC with 
125 μg/ml UA, the expression of ERK1, C-Myc, 
C-Jun, Cyclin D1 mRNA decreased with time 
(Figure 6); the expression of ERK1, C-Myc,C-
Jun,CyclinD1 were significantly different in the 





Figure 5: Expressions of ERK1, c-Jun, c-Myc, Cyclin 




Figure 6: Expressions of ERK1, c-Jun, c-Myc, Cyclin 





Chinese herbal medicines have been used in 
China for treatment of a wide variety of diseases 
with low adverse effects [6, 7]. UA is an α-
amyrin-type pentacyclic triterpenoid, and has 
wide biology effects, including inhibition of growth 
of various malignant cells [1]. Currently, its anti-
cancer effect is attracting considerable attention 
from pharmacologists. Angiogenesis is the key 
pathological process of tumor development and 
metastasis [8]. In tumor angiogenesis, activation, 
proliferation, migration and canaliculization of 
vascular endothelia cells (VEC) are important 
steps. Now many angiogenesis inhibitors, such 
as trotamine, interferon and platelet factor IV 
have been found but their clinical applications 
have been restricted because of high toxicity. As 
a potent new anti-tumor natural drug with high 
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anti-tumor effect and low toxicity, UA has vast 
potential as a new drug for cancer treatment [9]. 
 
Wang et al [10] suggested that UA has the ability 
to inhibit angiopoiesis of proliferative phase VEC 
in-vitro in a dose-dependent manner. Sohn et al 
[11] also obtained similar results using 
chorioallantoic membranes (CAM) of chicken 
embryo model. However, the mechanism of UA 
action is not yet clear. In our present study, we 
focused on the mechanism of inhibition of VEC 
proliferation by UA. PD98059 is a powerful ERK 
inhibitor which can selectively inhibit ERK activity 
so as to inhibit the proliferation of malignant 
glioma cells C6, thereby inducing their 
differentiation. The RT-PCR results of our 
present study show that expressions of ERK1, C-
Myc, C-Jun, CyclinD1 mRNA of HUVEC in UA 
group and PD98059 group were significantly 
lower than that of blank control group (p < 0.05) 
This indicates that both UA and PD98059 can 
inhibit the ERK signal pathway of HUVEC. 
Western blot results revealed that expressions of 
ERK1, C-Myc, C-Jun, CyclinD1 of HUVEC in UA 
group and PD98059 group were significantly 
lower than that of blank control group (p<0.05), 
and the results further demonstrate that UA can 
inhibit the ERK signal pathway of HUVEC, just 
like PD98059 effect, which is consistent with 
some literature reports 12,13]. Huang et al [14] 
suggested that the inhibition of ERK1/2 signal 
pathway may block VEC proliferation in their 
research on effects of tumstatin peptide on 
retinal microvascular endothelial cell (RMEC) 
proliferation. Therefore, we presume that UA and 
PD98059 can inhibit VEC proliferation by 
inhibiting the ERK signal pathway of HUVEC. 
Our results also show that the expressions of 
ERK1, C-Myc, C-Jun, Cyclin D1 mRNA and 
protein decreased gradually with UA dose and 
time and were significantly different between 
different dosage and time groups (p < 0.05). This 
shows that the inhibition of the ERK signal 





The findings of the present study indicate that the 
UA can significantly inhibit the generation of 
vascular endothelial cells of glioma by down-
regulating the expressions of ERK1, C-Jun, C-
Myc and Cyclin D1 of ERK signal transduction 
pathway, which is of potential value for the 
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